Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 889

1.

The plasma peptidome.

Dufresne J, Bowden P, Thavarajah T, Florentinus-Mefailoski A, Chen ZZ, Tucholska M, Norzin T, Ho MT, Phan M, Mohamed N, Ravandi A, Stanton E, Slutsky AS, Dos Santos CC, Romaschin A, Marshall JC, Addison C, Malone S, Heyland D, Scheltens P, Killestein J, Teunissen C, Diamandis EP, Siu KWM, Marshall JG.

Clin Proteomics. 2018 Dec 1;15:39. doi: 10.1186/s12014-018-9211-3. eCollection 2018.

2.

Current state of Alzheimer's fluid biomarkers.

Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J, Fagan AM, Hampel H, Mielke MM, Mikulskis A, O'Bryant S, Scheltens P, Sevigny J, Shaw LM, Soares HD, Tong G, Trojanowski JQ, Zetterberg H, Blennow K.

Acta Neuropathol. 2018 Dec;136(6):821-853. doi: 10.1007/s00401-018-1932-x. Epub 2018 Nov 28. Review.

PMID:
30488277
3.

Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study.

Legdeur N, Badissi M, Carter SF, de Crom S, van de Kreeke A, Vreeswijk R, Trappenburg MC, Oudega ML, Koek HL, van Campen JP, Keijsers CJPW, Amadi C, Hinz R, Gordon MF, Novak G, Podhorna J, Serné E, Verbraak F, Yaqub M, Hillebrand A, Griffa A, Pendleton N, Kramer SE, Teunissen CE, Lammertsma A, Barkhof F, van Berckel BNM, Scheltens P, Muller M, Maier AB, Herholz K, Visser PJ.

BMC Geriatr. 2018 Nov 26;18(1):289. doi: 10.1186/s12877-018-0984-z.

4.

Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy.

Chakraborty A, Kamermans A, van Het Hof B, Castricum K, Aanhane E, van Horssen J, Thijssen VL, Scheltens P, Teunissen CE, Fontijn RD, van der Flier WM, de Vries HE.

Brain. 2018 Dec 1;141(12):3377-3388. doi: 10.1093/brain/awy274.

PMID:
30462206
5.

Secondary prevention of Alzheimer's dementia: neuroimaging contributions.

Ten Kate M, Ingala S, Schwarz AJ, Fox NC, Chételat G, van Berckel BNM, Ewers M, Foley C, Gispert JD, Hill D, Irizarry MC, Lammertsma AA, Molinuevo JL, Ritchie C, Scheltens P, Schmidt ME, Visser PJ, Waldman A, Wardlaw J, Haller S, Barkhof F.

Alzheimers Res Ther. 2018 Oct 30;10(1):112. doi: 10.1186/s13195-018-0438-z.

6.

Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease.

Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg OT, Schöll M, Dansereau C, Villeneuve S, van der Flier WM, Scheltens P, Bellec P, Evans AC, Hansson O, Ossenkoppele R; Alzheimer's Disease Neuroimaging Initiative; Swedish BioFINDER Study.

Hum Brain Mapp. 2018 Oct 19. doi: 10.1002/hbm.24401. [Epub ahead of print]

PMID:
30368979
7.

Predicting progression in the late onset frontal lobe syndrome.

Gossink FT, Vijverberg E, Krudop W, Scheltens P, Stek ML, Pijnenburg YAL, Dols A.

Int Psychogeriatr. 2018 Oct 26:1-6. doi: 10.1017/S1041610218001242. [Epub ahead of print]

PMID:
30362933
8.

The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort description.

Holstege H, Beker N, Dijkstra T, Pieterse K, Wemmenhove E, Schouten K, Thiessens L, Horsten D, Rechtuijt S, Sikkes S, van Poppel FWA, Meijers-Heijboer H, Hulsman M, Scheltens P.

Eur J Epidemiol. 2018 Dec;33(12):1229-1249. doi: 10.1007/s10654-018-0451-3. Epub 2018 Oct 25.

PMID:
30362018
9.

Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline.

Ten Kate M, Dicks E, Visser PJ, van der Flier WM, Teunissen CE, Barkhof F, Scheltens P, Tijms BM; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2018 Dec 1;141(12):3443-3456. doi: 10.1093/brain/awy264.

PMID:
30351346
10.

Clinical phenotype, atrophy, and small vessel disease in APOEε2 carriers with Alzheimer disease.

Groot C, Sudre CH, Barkhof F, Teunissen CE, van Berckel BNM, Seo SW, Ourselin S, Scheltens P, Cardoso MJ, van der Flier WM, Ossenkoppele R.

Neurology. 2018 Nov 13;91(20):e1851-e1859. doi: 10.1212/WNL.0000000000006503. Epub 2018 Oct 19.

PMID:
30341156
11.

AMYPAD Diagnostic and Patient Management Study: Rationale and design.

Frisoni GB, Barkhof F, Altomare D, Berkhof J, Boccardi M, Canzoneri E, Collij L, Drzezga A, Farrar G, Garibotto V, Gismondi R, Gispert JD, Jessen F, Kivipelto M, Alves IL, Molinuevo JL, Nordberg A, Payoux P, Ritchie C, Savicheva I, Scheltens P, Schmidt ME, Schott J, Stephens A, van Berckel B, Vellas B, Walker Z, Raffa N.

Alzheimers Dement. 2018 Oct 16. pii: S1552-5260(18)33528-3. doi: 10.1016/j.jalz.2018.09.003. [Epub ahead of print]

12.

Evaluating combinations of diagnostic tests to discriminate different dementia types.

Bruun M, Rhodius-Meester HFM, Koikkalainen J, Baroni M, Gjerum L, Lemstra AW, Barkhof F, Remes AM, Urhemaa T, Tolonen A, Rueckert D, van Gils M, Frederiksen KS, Waldemar G, Scheltens P, Mecocci P, Soininen H, Lötjönen J, Hasselbalch SG, van der Flier WM.

Alzheimers Dement (Amst). 2018 Aug 17;10:509-518. doi: 10.1016/j.dadm.2018.07.003. eCollection 2018.

13.

Assessing Amyloid Pathology in Cognitively Normal Subjects using [18F]Flutemetamol PET: Comparing Visual Reads and Quantitative Methods.

Collij L, Konijnenberg E, Reimand J, Ten Kate M, Den Braber A, Lopes Alves I, Zwan M, Yaqub M, Van Assema D, Wink AM, Lammertsma A, Scheltens P, Visser PJ, Barkhof F, Van Berckel B.

J Nucl Med. 2018 Oct 12. pii: jnumed.118.211532. doi: 10.2967/jnumed.118.211532. [Epub ahead of print]

PMID:
30315145
14.

Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease.

Gardiner SL, Harder AVE, Campman YJM, Trompet S, Gussekloo J, van Belzen MJ, Boogaard MW, Roos RAC, Jansen IE, Pijnenburg YAL, Scheltens P, van der Flier WM, Aziz NA.

Neurobiol Aging. 2019 Jan;73:230.e9-230.e17. doi: 10.1016/j.neurobiolaging.2018.09.007. Epub 2018 Sep 15.

PMID:
30314815
15.

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.

Scheltens P, Hallikainen M, Grimmer T, Duning T, Gouw AA, Teunissen CE, Wink AM, Maruff P, Harrison J, van Baal CM, Bruins S, Lues I, Prins ND.

Alzheimers Res Ther. 2018 Oct 12;10(1):107. doi: 10.1186/s13195-018-0431-6.

16.

MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study.

Ten Kate M, Redolfi A, Peira E, Bos I, Vos SJ, Vandenberghe R, Gabel S, Schaeverbeke J, Scheltens P, Blin O, Richardson JC, Bordet R, Wallin A, Eckerstrom C, Molinuevo JL, Engelborghs S, Van Broeckhoven C, Martinez-Lage P, Popp J, Tsolaki M, Verhey FRJ, Baird AL, Legido-Quigley C, Bertram L, Dobricic V, Zetterberg H, Lovestone S, Streffer J, Bianchetti S, Novak GP, Revillard J, Gordon MF, Xie Z, Wottschel V, Frisoni G, Visser PJ, Barkhof F.

Alzheimers Res Ther. 2018 Sep 27;10(1):100. doi: 10.1186/s13195-018-0428-1.

17.

Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.

Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P; SCarlet RoAD Investigators.

Alzheimers Res Ther. 2018 Sep 27;10(1):99. doi: 10.1186/s13195-018-0409-4.

18.

Centenarian controls increase variant effect sizes by an average twofold in an extreme case-extreme control analysis of Alzheimer's disease.

Tesi N, van der Lee SJ, Hulsman M, Jansen IE, Stringa N, van Schoor N, Meijers-Heijboer H, Huisman M, Scheltens P, Reinders MJT, van der Flier WM, Holstege H.

Eur J Hum Genet. 2018 Sep 26. doi: 10.1038/s41431-018-0273-5. [Epub ahead of print]

PMID:
30258121
19.

Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia.

Bergeron D, Gorno-Tempini ML, Rabinovici GD, Santos-Santos MA, Seeley W, Miller BL, Pijnenburg Y, Keulen MA, Groot C, van Berckel BNM, van der Flier WM, Scheltens P, Rohrer JD, Warren JD, Schott JM, Fox NC, Sanchez-Valle R, Grau-Rivera O, Gelpi E, Seelaar H, Papma JM, van Swieten JC, Hodges JR, Leyton CE, Piguet O, Rogalski EJ, Mesulam MM, Koric L, Nora K, Pariente J, Dickerson B, Mackenzie IR, Hsiung GR, Belliard S, Irwin DJ, Wolk DA, Grossman M, Jones M, Harris J, Mann D, Snowden JS, Chrem-Mendez P, Calandri IL, Amengual AA, Miguet-Alfonsi C, Magnin E, Magnani G, Santangelo R, Deramecourt V, Pasquier F, Mattsson N, Nilsson C, Hansson O, Keith J, Masellis M, Black SE, Matías-Guiu JA, Cabrera-Martin MN, Paquet C, Dumurgier J, Teichmann M, Sarazin M, Bottlaender M, Dubois B, Rowe CC, Villemagne VL, Vandenberghe R, Granadillo E, Teng E, Mendez M, Meyer PT, Frings L, Lleó A, Blesa R, Fortea J, Seo SW, Diehl-Schmid J, Grimmer T, Frederiksen KS, Sánchez-Juan P, Chételat G, Jansen W, Bouchard RW, Laforce RJ, Visser PJ, Ossenkoppele R.

Ann Neurol. 2018 Nov;84(5):729-740. doi: 10.1002/ana.25333.

PMID:
30255971
20.

Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals.

Tijms BM, Vermunt L, Zwan MD, van Harten AC, van der Flier WM, Teunissen CE, Scheltens P, Visser PJ; for ADNI.

Ann Clin Transl Neurol. 2018 Jul 20;5(9):1037-1047. doi: 10.1002/acn3.615. eCollection 2018 Sep.

21.

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes.

Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM, Scheltens P, Teunissen CE, van der Flier WM.

Ann Neurol. 2018 Nov;84(5):648-658. doi: 10.1002/ana.25334. Epub 2018 Oct 4.

PMID:
30196548
22.

Gray matter atrophy in dementia with Lewy bodies with and without concomitant Alzheimer's disease pathology.

van der Zande JJ, Steenwijk MD, Ten Kate M, Wattjes MP, Scheltens P, Lemstra AW.

Neurobiol Aging. 2018 Nov;71:171-178. doi: 10.1016/j.neurobiolaging.2018.07.005. Epub 2018 Jul 17.

PMID:
30149288
23.

A novel partial volume correction method for accurate quantification of [18F] flortaucipir in the hippocampus.

Wolters EE, Golla SSV, Timmers T, Ossenkoppele R, van der Weijden CWJ, Scheltens P, Schwarte L, Schuit RC, Windhorst AD, Barkhof F, Yaqub M, Lammertsma AA, Boellaard R, van Berckel BNM.

EJNMMI Res. 2018 Aug 15;8(1):79. doi: 10.1186/s13550-018-0432-2.

24.

Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression.

Scheltens NME, Tijms BM, Heymans MW, Rabinovici GD, Cohn-Sheehy BI, Miller BL, Kramer JH, Wolfsgruber S, Wagner M, Kornhuber J, Peters O, Scheltens P, van der Flier WM; Amsterdam Dementia Cohort, Alzheimer’s Disease Neuroimaging Initiative, German Dementia Competence Network, University of San Francisco Memory and Aging Center.

J Alzheimers Dis. 2018;65(3):1029-1039. doi: 10.3233/JAD-171088.

PMID:
30103316
25.

Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results.

Slot RER, Verfaillie SCJ, Overbeek JM, Timmers T, Wesselman LMP, Teunissen CE, Dols A, Bouwman FH, Prins ND, Barkhof F, Lammertsma AA, Van Berckel BNM, Scheltens P, Sikkes SAM, Van der Flier WM.

Alzheimers Res Ther. 2018 Aug 7;10(1):76. doi: 10.1186/s13195-018-0390-y.

26.

The EMIF-AD PreclinAD study: study design and baseline cohort overview.

Konijnenberg E, Carter SF, Ten Kate M, den Braber A, Tomassen J, Amadi C, Wesselman L, Nguyen HT, van de Kreeke JA, Yaqub M, Demuru M, Mulder SD, Hillebrand A, Bouwman FH, Teunissen CE, Serné EH, Moll AC, Verbraak FD, Hinz R, Pendleton N, Lammertsma AA, van Berckel BNM, Barkhof F, Boomsma DI, Scheltens P, Herholz K, Visser PJ.

Alzheimers Res Ther. 2018 Aug 4;10(1):75. doi: 10.1186/s13195-018-0406-7.

27.

An intervention programme for caregivers of dementia patients with frontal behavioural changes: an explorative study with controlled effect on sense of competence.

Gossink F, Pijnenburg Y, Scheltens P, Pera A, Kleverwal R, Korten N, Stek M, Dröes RM, Dols A.

Psychogeriatrics. 2018 Nov;18(6):451-459. doi: 10.1111/psyg.12351. Epub 2018 Jul 31.

PMID:
30066463
28.

Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.

de Wilde A, van Buchem MM, Otten RHJ, Bouwman F, Stephens A, Barkhof F, Scheltens P, van der Flier WM.

Alzheimers Res Ther. 2018 Jul 28;10(1):72. doi: 10.1186/s13195-018-0398-3. Review.

29.

Survival in memory clinic cohort is short, even in young-onset dementia.

Rhodius-Meester HFM, Tijms BM, Lemstra AW, Prins ND, Pijnenburg YAL, Bouwman F, Scheltens P, van der Flier WM.

J Neurol Neurosurg Psychiatry. 2018 Jul 25. pii: jnnp-2018-318820. doi: 10.1136/jnnp-2018-318820. [Epub ahead of print] No abstract available.

30.

Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinson's Disease.

Ciliz M, Sartor J, Lindig T, Pilotto A, Schäffer E, Weiss M, Scheltens P, Becker S, Hobert MA, Berg D, Liepelt-Scarfone I, Maetzler W.

J Parkinsons Dis. 2018;8(3):455-462. doi: 10.3233/JPD-181351.

PMID:
30040742
31.

Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma.

Groot C, Tolboom N, Ikonomovic MD, Lammertsma AA, Boon BDC, Barkhof F, Scheltens P, Klunk WE, Rozemuller AJM, Ossenkoppele R, van Berckel BNM.

J Alzheimers Dis. 2018;65(1):71-77. doi: 10.3233/JAD-180316.

PMID:
30040724
32.

Neuropathology and cognitive performance in self-reported cognitively healthy centenarians.

Ganz AB, Beker N, Hulsman M, Sikkes S, Netherlands Brain Bank, Scheltens P, Smit AB, Rozemuller AJM, Hoozemans JJM, Holstege H.

Acta Neuropathol Commun. 2018 Jul 23;6(1):64. doi: 10.1186/s40478-018-0558-5.

33.

EEG Characteristics of Dementia With Lewy Bodies, Alzheimer's Disease and Mixed Pathology.

van der Zande JJ, Gouw AA, van Steenoven I, Scheltens P, Stam CJ, Lemstra AW.

Front Aging Neurosci. 2018 Jul 3;10:190. doi: 10.3389/fnagi.2018.00190. eCollection 2018.

34.

Understanding hallucinations in probable Alzheimer's disease: Very low prevalence rates in a tertiary memory clinic.

Linszen MMJ, Lemstra AW, Dauwan M, Brouwer RM, Scheltens P, Sommer IEC.

Alzheimers Dement (Amst). 2018 Apr 21;10:358-362. doi: 10.1016/j.dadm.2018.03.005. eCollection 2018.

35.

Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease.

Scheltens NME, van der Weijden K, Adriaanse SM, van Assema D, Oomen PP, Krudop WA, Lammertsma AA, Barkhof F, Koene T, Teunissen CE, Scheltens P, van der Flier WM, Pijnenburg YAL, Yaqub M, Ossenkoppele R, van Berckel BNM.

Neuroimage Clin. 2018 May 22;19:625-632. doi: 10.1016/j.nicl.2018.05.024. eCollection 2018.

36.

The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics.

Bos I, Vos S, Vandenberghe R, Scheltens P, Engelborghs S, Frisoni G, Molinuevo JL, Wallin A, Lleó A, Popp J, Martinez-Lage P, Baird A, Dobson R, Legido-Quigley C, Sleegers K, Van Broeckhoven C, Bertram L, Ten Kate M, Barkhof F, Zetterberg H, Lovestone S, Streffer J, Visser PJ.

Alzheimers Res Ther. 2018 Jul 6;10(1):64. doi: 10.1186/s13195-018-0396-5.

37.

What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force.

Aisen PS, Siemers E, Michelson D, Salloway S, Sampaio C, Carrillo MC, Sperling R, Doody R, Scheltens P, Bateman R, Weiner M, Vellas B.

J Prev Alzheimers Dis. 2018;5(3):171-174. doi: 10.14283/jpad.2018.23.

PMID:
29972209
38.

Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia.

Chakraborty A, Chatterjee M, Twaalfhoven H, Del Campo Milan M, Teunissen CE, Scheltens P, Fontijn RD, van Der Flier WM, de Vries HE.

Alzheimers Res Ther. 2018 Jun 23;10(1):58. doi: 10.1186/s13195-018-0385-8.

39.

Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.

Bos I, Verhey FR, Ramakers IHGB, Jacobs HIL, Soininen H, Freund-Levi Y, Hampel H, Tsolaki M, Wallin ÅK, van Buchem MA, Oleksik A, Verbeek MM, Rikkert MO, van der Flier WM, Scheltens P, Aalten P, Visser PJ, Vos SJB.

Alzheimers Res Ther. 2018 Jun 20;10(1):56. doi: 10.1186/s13195-018-0391-x.

40.

Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier.

Tolonen A, Rhodius-Meester HFM, Bruun M, Koikkalainen J, Barkhof F, Lemstra AW, Koene T, Scheltens P, Teunissen CE, Tong T, Guerrero R, Schuh A, Ledig C, Baroni M, Rueckert D, Soininen H, Remes AM, Waldemar G, Hasselbalch SG, Mecocci P, van der Flier WM, Lötjönen J.

Front Aging Neurosci. 2018 Apr 25;10:111. doi: 10.3389/fnagi.2018.00111. eCollection 2018.

41.

Quantification of [18F]florbetapir: A test-retest tracer kinetic modelling study.

Golla SS, Verfaillie SC, Boellaard R, Adriaanse SM, Zwan MD, Schuit RC, Timmers T, Groot C, Schober P, Scheltens P, van der Flier WM, Windhorst AD, van Berckel BN, Lammertsma AA.

J Cereb Blood Flow Metab. 2018 Jun 13:271678X18783628. doi: 10.1177/0271678X18783628. [Epub ahead of print]

PMID:
29897009
42.

Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project.

de Wilde A, van der Flier WM, Pelkmans W, Bouwman F, Verwer J, Groot C, van Buchem MM, Zwan M, Ossenkoppele R, Yaqub M, Kunneman M, Smets EMA, Barkhof F, Lammertsma AA, Stephens A, van Lier E, Biessels GJ, van Berckel BN, Scheltens P.

JAMA Neurol. 2018 Sep 1;75(9):1062-1070. doi: 10.1001/jamaneurol.2018.1346.

PMID:
29889941
43.

Medial temporal lobe atrophy relates more strongly to sleep-wake rhythm fragmentation than to age or any other known risk.

Van Someren EJW, Oosterman JM, Van Harten B, Vogels RL, Gouw AA, Weinstein HC, Poggesi A, Scheltens P, Scherder EJA.

Neurobiol Learn Mem. 2018 Jun 1. pii: S1074-7427(18)30128-X. doi: 10.1016/j.nlm.2018.05.017. [Epub ahead of print]

44.

Neuroinflammation is increased in the parietal cortex of atypical Alzheimer's disease.

Boon BDC, Hoozemans JJM, Lopuhaä B, Eigenhuis KN, Scheltens P, Kamphorst W, Rozemuller AJM, Bouwman FH.

J Neuroinflammation. 2018 May 29;15(1):170. doi: 10.1186/s12974-018-1180-y.

45.

A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test-retest reliability and feasibility.

Jutten RJ, Harrison J, Lee Meeuw Kjoe PR, Opmeer EM, Schoonenboom NSM, de Jong FJ, Ritchie CW, Scheltens P, Sikkes SAM.

Alzheimers Dement (Amst). 2017 Dec 27;10:153-160. doi: 10.1016/j.dadm.2017.12.002. eCollection 2018.

46.

Microbleeds are associated with depressive symptoms in Alzheimer's disease.

Leeuwis AE, Prins ND, Hooghiemstra AM, Benedictus MR, Scheltens P, Barkhof F, van der Flier WM.

Alzheimers Dement (Amst). 2017 Dec 6;10:112-120. doi: 10.1016/j.dadm.2017.11.006. eCollection 2018.

47.

Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease.

Verfaillie SCJ, Pichet Binette A, Vachon-Presseau E, Tabrizi S, Savard M, Bellec P, Ossenkoppele R, Scheltens P, van der Flier WM, Breitner JCS, Villeneuve S; PREVENT-AD Research Group.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 May;3(5):463-472. doi: 10.1016/j.bpsc.2017.11.012. Epub 2017 Dec 14.

PMID:
29735156
48.

Cerebral White Matter Lesions have Low Impact on Cognitive Function in a Large Elderly Memory Clinic Population.

Claus JJ, Coenen M, Staekenborg SS, Schuur J, Tielkes CEM, Koster P, Scheltens P.

J Alzheimers Dis. 2018;63(3):1129-1139. doi: 10.3233/JAD-171111.

PMID:
29710708
49.

An exploratory clinical study of p38α kinase inhibition in Alzheimer's disease.

Scheltens P, Prins N, Lammertsma A, Yaqub M, Gouw A, Wink AM, Chu HM, van Berckel BNM, Alam J.

Ann Clin Transl Neurol. 2018 Mar 6;5(4):464-473. doi: 10.1002/acn3.549. eCollection 2018 Apr.

50.

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors.

Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018. Review.

Supplemental Content

Loading ...
Support Center